Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 15, 2019

View Archived Issues

ALKBH proteins are potential therapeutic targets in HNSCC

Novel GET zebrafish larvae model of invasive mycoses

GalNAc-siTAZ improves hepatic inflammation, fibrosis and liver damage in models of NASH

Targeting Piezo1 channel as promising new therapeutic strategy in prostate cancer

Reservoir grows when ART starts

Accidental immunity gives rotavirus insight

Ironing out regional differences affects anxiety

Patient enrollment under way in phase I study of FT-516

Matinas BioPharma initiates EnACT study of MAT-2203 for fungal cryptococcal meningitis

Wuhan Institute of Virology describes respiratory syncytial virus vaccine antigen

Novel PSMA-targeting 177-Lu radiolabeled compounds with outstanding tumor uptake presented

Recombinant Clonorchis sinensis heat shock cognate protein B patented by Xuzhou Medical University

Bristol-Myers Squibb identifies new TYK2 inhibitors

Intra-Cellular Therapies discovers 5-HT2A antagonists/mu-opioid receptor partial agonists

DE Shaw Research and Relay Therapeutics disclose PTPN11 inhibitors

Progression-free survival improved with ivosidenib in pivotal cholangiocarcinoma trial

NMSS grant supports Clene's development of nanocatalytic therapeutic CNM-Au8 for MS

Immunotherapy frontiers: 'Strength in numbers', 'it only takes one' both true for neoantigens

Primary endpoint met in registrational MOXIe trial of omaveloxolone for Friedreich's ataxia

Collaborative Medicinal Development enrolls first patient in new study of CuATSM for ALS

Viela Bio enrolling kidney transplant recipients for phase IIa trial of VIB-4920 and belatacept

AstraZeneca initiates first-in-human study of AZD-4041 in healthy volunteers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...